---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000009"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T12:15:08.418987+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech Q4 revenue $91.1M (+116% YoY); net income $45.5M; FY revenue $290.5M

## Summary
- Q4 2024 product revenue $91.1M (+116% YoY); full year $290.5M (+473% vs 2023).
- Q4 2024 net income $45.5M ($1.58 basic EPS) vs $8.7M ($0.31) in Q4 2023.
- Cash, cash eq & investments $749.6M as of Dec 31, 2024.
- Pipeline: KB707 solid tumors ORR 27%; KB408 AATD interim positive; CFF sanctioned KB407 CF study.
- FY2025 non-GAAP R&D+SG&A guidance $150-175M.

## SEC filing metadata
- accession: 0001711279-25-000009
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/0001711279-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000009/krys-20250219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000009
- JSON: https://secwatch.observer/filing/0001711279-25-000009.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.